Features | VJHemOnc

ISAL 2017: Developments in acute leukemias

The International Symposium on Acute Leukemias (ISAL) 2017 was, as always, filled with data, scientific developments and debate. To capture…

Innovative Medicines Initiative approves €40 million HARMONY project for better care of patients with hematologic malignancies

The Innovative Medicines Initiative (IMI) has approved HARMONY, a project that aims to foster better access and care for patients…

The bone marrow mesenchymal stem cell: exploring its role in MGUS and multiple myeloma

Multiple myeloma (MM) is an incurable malignant disease of plasma cells, representing the most severe form of paraproteinaemia. In most…

TIDEL II trial: uncovering the predictive value of ABCB1 in determining the long-term response to imatinib in CML patients

Adelaide researchers based at the South Australian Health and Medical Research Institute (SAHMRI) have demonstrated the significance of early increases…

ASCO/EHA 2016: Combination therapies change the standard of care in multiple myeloma

As usual, the ASCO Annual Meeting and the EHA Annual Congress were a hub of activity, data and discussion. We…

Positive Phase III results for plitidepsin

Plitidepsin (also known as dehydrodidemnin B) is a first-in-class drug originally obtained from the sea squirt Aplidium albicans.[1] Plitidepsin specifically…

Solving the CARD11 puzzle and gaining a deeper understanding of oncogenic mutations

CARD11 is a scaffold protein that is critical for antigen receptor signaling. Normally, it is locked in an “off” position…

New tyrosine kinase inhibitor shows promise

MRX-2843 is a tyrosine kinase inhibitor that targets the receptor tyrosine kinases MERTK and FLT3. Both MERTK and FLT3 are…